The structure of cyclocreatine is fairly flat (planar), which aids in passive diffusion across membranes. It has been used with success in an animal study, where mice suffered from a SLC6A8 (creatine transporter at the blood brain barrier) deficiency, which is not responsive to standard creatine supplementation.  This study failed to report increases in creatine stores in the brain, but noted a reduction of mental retardation associated with increased cyclocreatine and phosphorylated cyclocreatine storages.  As demonstrated by this animal study and previous ones, cyclocreatine is bioactive after oral ingestion   and may merely be a creatine mimetic, able to phosphorylate ADP via the creatine kinase system. 
There have been attempts to link squalene to Gulf War Syndrome mainly due to the idea that squalene might have been present in an anthrax vaccine given to some military personnel during the 1991 Persian Gulf War. Studies found that deployed Persian Gulf War Syndrome patients are significantly more likely to have antibodies to squalene (95 percent) than asymptomatic Gulf War veterans (0 percent; p<.001).   The first of these published results concludes with the following statement: "It is important to note that our laboratory-based investigations do not establish that squalene was added as adjuvant to any vaccine used in military or other personnel who served in the Persian Gulf War era." The second publication, however, links the incidence of anti-squalene antibodies and Gulf War Syndrome to five specific lots of vaccine. Furthermore, they cite results of 1999 testing by the . Food and Drug Administration which found these specific lots of vaccine to contain squalene.  In response to these results, a committee of the US Institute of Medicine stated that "The committee does not regard this study as providing evidence that the investigators have successfully measured antibodies to squalene", since the authors did not perform the normal scientific controls needed to show that their test was specific to anti-squalene antibodies.  It has also been determined that the anthrax vaccines given to those US military personnel did not use squalene as an adjuvant.    The vaccines were also tested for squalene, and none was detected with standard methods.  Another method found no squalene in 37 of the 38 lots tested. One lot contained traces of squalene, at less than ten parts per billion, which is about one-thirtieth the level found in human blood.  The FDA stated that this trace of squalene probably came from a fingerprint, since the oils on human skin contain enough squalene to send these extremely sensitive tests "off the chart".